University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Bruce Cree, Ph.D., M.D.

Neurologist

Dr. Bruce Cree is a neurologist with a special interest in multiple sclerosis. In addition to providing patient care, Cree focuses on the development of novel therapies through clinical trials. Cree received his medical degree and doctorate in biochemistry from the University of California, San Francisco. He went on to complete his neurology residency at Columbia University. Cree is the recipient of a National Institute of Health post-doctoral grant for multiple sclerosis clinical research and is a Sylvia Lawry fellow of the National Multiple Sclerosis Society.

Clinics

Multiple Sclerosis Center
1500 Owens St., Suite 320
San Francisco, CA 94158
Phone: (415) 353-2069
Fax: (415) 353-2633

Hours: Monday to Friday
8:30 a.m. – 4:30 p.m.

Conditions & Treatments

More about Bruce Cree

Education

UCSF School of Medicine 1997

Residencies

Columbia Presbyterian Medical Center, Neurology 2001

Fellowships

UCSF Medical Center, Neurology 2003

Selected Research and Publications

  1. Cree BA. 2014 multiple sclerosis therapeutic update. Neurohospitalist. 2014 Apr; 4(2):63-5.
  2. Fox RJ, Cree BA, De Sèze J, Gold R, Hartung HP, Jeffery D, Kappos L, Kaufman M, Montalbán X, Weinstock-Guttman B, Anderson B, Natarajan A, Ticho B, Duda P. MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study. Neurology. 2014 Apr 29; 82(17):1491-8.
  3. Bevan CJ, Cree BA. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? JAMA Neurol. 2014 Mar 1; 71(3):269-70.
  4. Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014 Mar; 13(3):257-67.
  5. Cree BA. Multiple sclerosis genetics. Handb Clin Neurol. 2014; 122:193-209.
  6. Cree BA. Genetics of primary progressive multiple sclerosis. Handb Clin Neurol. 2014; 122:211-30.
  7. Cree BA. Acute inflammatory myelopathies. Handb Clin Neurol. 2014; 122:613-67.
  8. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013 Nov; 45(11):1353-60.
  9. Isobe N, Gourraud PA, Harbo HF, Caillier SJ, Santaniello A, Khankhanian P, Maiers M, Spellman S, Cereb N, Yang S, Pando MJ, Piccio L, Cross AH, De Jager PL, Cree BA, Hauser SL, Oksenberg JR. Genetic risk variants in African Americans with multiple sclerosis. Neurology. 2013 Jul 16; 81(3):219-27.
  10. Nickles D, Chen HP, Li MM, Khankhanian P, Madireddy L, Caillier SJ, Santaniello A, Cree BA, Pelletier D, Hauser SL, Oksenberg JR, Baranzini SE. Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Hum Mol Genet. 2013 Oct 15; 22(20):4194-205.
  11. Gelfand JM, Cree BA, Nolan R, Arnow S, Green AJ. Microcystic inner nuclear layer abnormalities and neuromyelitis optica. JAMA Neurol. 2013 May; 70(5):629-33.
  12. Greenberg BM, Balcer L, Calabresi PA, Cree B, Cross A, Frohman T, Gold R, Havrdova E, Hemmer B, Kieseier BC, Lisak R, Miller A, Racke MK, Steinman L, Stuve O, Wiendl H, Frohman E. Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis. JAMA Neurol. 2013 Feb; 70(2):248-51.
  13. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler. 2013 Jun; 19(7):835-43.
  14. von Büdingen HC, Kuo TC, Sirota M, van Belle CJ, Apeltsin L, Glanville J, Cree BA, Gourraud PA, Schwartzburg A, Huerta G, Telman D, Sundar PD, Casey T, Cox DR, Hauser SL. B cell exchange across the blood-brain barrier in multiple sclerosis. J Clin Invest. 2012 Dec 3; 122(12):4533-43.
  15. West TW, Hess C, Cree BA. Acute transverse myelitis: demyelinating, inflammatory, and infectious myelopathies. Semin Neurol. 2012 Apr; 32(2):97-113.
  16. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BA, Zamvil SS. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol. 2012 Jul; 72(1):53-64.
  17. Menge T, Cree B, Saleh A, Waterboer T, Berthele A, Kalluri SR, Hemmer B, Aktas O, Hartung HP, Methner A, Kieseier BC. Neuromyelitis optica following human papillomavirus vaccination. Neurology. 2012 Jul 17; 79(3):285-7.
  18. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 Aug 11; 476(7359):214-9.
  19. Gelfand JM, Cree BA, McElroy J, Oksenberg J, Green R, Mowry EM, Miller JW, Hauser SL, Green AJ. Vitamin D in African Americans with multiple sclerosis. Neurology. 2011 May 24; 76(21):1824-30.
  20. Nakashima I, Takahashi T, Cree BA, Kim HJ, Suzuki C, Genain CP, Vincent T, Fujihara K, Itoyama Y, Bar-Or A. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci. 2011 Jul; 18(7):997-8.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.